Related Experiment Video
Updated: Jun 23, 2026
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Degarelix for prostate cancer
Christian Doehn1, Martin Sommerauer, Dieter Jocham
1Department of Urology, University of Lübeck Medical School, Ratzeburger Allee 160, Lübeck, Germany. doehn@medinf.mu-luebeck.de
Abstract:
The growth of prostate cancer cells is hormone dependent in the majority of patients with the disease. Lowering testosterone either surgically or medically (usually with a gonadotropin releasing hormone (GnRH) agonist) is the standard of care in patients with metastatic prostate cancer. Degarelix is a new GnRH antagonist for the treatment of patients with prostate cancer. In contrast to GnRH agonists, the development of GnRH antagonists was hindered for a long time owing to histamine-releasing activity and lack of potency and water solubility. Recently, however, degarelix has been approved by the FDA for the treatment of advanced prostate cancer. This review summarizes the preclinical and clinical data available for degarelix and describes its potential role in the market of prostate cancer therapeutics.
Insights
Degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist, offers a novel treatment for advanced prostate cancer. It effectively lowers testosterone, providing an alternative to GnRH agonists for hormone-dependent cancer.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Prostate cancer growth is often hormone-dependent, necessitating testosterone suppression.
- Current standard of care involves surgical or medical castration using gonadotropin-releasing hormone (GnRH) agonists.
- GnRH antagonists faced development challenges, including histamine release and poor solubility.
Purpose of the Study:
- To review preclinical and clinical data for degarelix.
- To assess the potential role of degarelix in prostate cancer therapeutics.
Main Methods:
- Review of published preclinical studies.
- Analysis of clinical trial data for degarelix efficacy and safety.
- Market analysis of prostate cancer treatment landscape.
Main Results:
- Degarelix is a newly approved GnRH antagonist by the FDA for advanced prostate cancer.
- Overcame previous limitations of GnRH antagonists, such as histamine release and solubility issues.
- Demonstrated efficacy in lowering testosterone levels.
Conclusions:
- Degarelix represents a significant advancement in prostate cancer treatment.
- Offers a new therapeutic option for patients with hormone-dependent prostate cancer.
- Potential to capture a notable market share in prostate cancer therapeutics.
